International Business Machines (NYSE:IBM) Launches Watsonx AI Labs In New York City
International Business Machines recently announced the launch of Watsonx AI Labs, a significant business expansion aiming to enhance AI capabilities and collaboration in New York City. During the past month, IBM's stock price moved by 7%, a figure that substantially exceeds the market's 2% climb in the past week. While IBM's innovations in AI, such as the partnership with Deutsche Bank and the Deca Technologies collaboration, align with the market's positive sentiment, these developments would have added weight to the broader upward trend observed in the stock price.
Every company has risks, and we've spotted 5 risks for International Business Machines you should know about.
The end of cancer? These 23 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
The launch of Watsonx AI Labs is a pivotal development for IBM, potentially influencing its future prospects significantly. This initiative aligns with IBM's focus on AI and cloud services, two sectors that have been earmarked for potential growth. Over the past five years, IBM's total return, including share price appreciation and dividends, has been 154.16%. This performance provides a broader context beyond the recent 7% stock price increase driven by Watsonx's announcement.
IBM's shares have outperformed the US IT industry and the broader market over the last year, with its return far exceeding both benchmarks. While the industry saw less than half of IBM's gain, this underscores investor confidence in IBM's innovations, including the AI labs and collaborations like those with Deutsche Bank. However, the current share price of US$253.37, which exceeds consensus analyst fair value estimates, raises questions about future growth sustainability if market conditions change. The price target reflects a 4% discount to its recent market valuation.
The Watsonx AI Labs could further enhance revenue and earnings forecasts by boosting IBM's AI and consulting offerings. Yet, IBM's reliance on economic stability and cloud adoption highlights potential vulnerabilities, as indicated by the range in analyst price targets. The integration of AI and hybrid cloud services aims to mitigate these risks. Still, the consensus fair value of US$252.27 suggests that market expectations may already encompass some of these anticipated benefits. As IBM presses forward with its strategic initiatives, ongoing evaluations of these factors will be crucial for potential investors.
According our valuation report, there's an indication that International Business Machines' share price might be on the expensive side.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NYSE:IBM.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Opinion: Science is Utah's quiet engine — don't stall it with cuts to important funding
Science quietly powers Utah's prosperity. From lifesaving diagnostics at ARUP Laboratories and cutting-edge biotech startups to clean energy research at Utah State and drought-resistant crops developed through university partnerships, science is behind much of what makes life in Utah better, longer and more secure. In 2024, the National Institutes of Health (NIH) awarded over $300 million to Utah institutions. That funding supported thousands of jobs, helped launch companies, and enabled groundbreaking research in everything from cancer treatments to Alzheimer's to rare disease therapies. Public health advances that benefit every Utahn — urban or rural — almost always begin through federally funded research. But now, that progress is in jeopardy. Proposed cuts and restrictions to NIH funding could have devastating effects on Utah's research institutions and economy. The plan to slash NIH's overall budget by nearly half, coupled with a proposal to reduce the indirect cost reimbursement to universities from around 50% to 15%, would mean far less money to cover the real costs of doing science. Basics like lab space, utilities, data storage and administrative support aren't luxuries — they're the infrastructure that makes research possible. For public universities like the University of Utah and Utah State, this isn't just a budget concern. It's a structural threat. Without adequate indirect cost support, universities would either have to drastically scale back research activity or shift the financial burden to students and state taxpayers. Both options would weaken Utah's competitive edge in science and technology. The consequences would ripple far beyond campus. Utah is known for its 'Industry' motto — a title that honors the resourcefulness and hard work that built our communities. Today, that industrious spirit thrives in our biotech labs, clean tech startups and health research centers. But industries can't thrive without innovation. Utah's life sciences sector depends on a steady pipeline of NIH-supported talent and discoveries emerging from research. Companies like Recursion, Myriad Genetics and BioFire Diagnostics thrive because of academic partnerships and access to skilled graduates. Pulling funding would slow innovation and shrink the talent pool. But it's not just about economics. It's about people. NIH funding supports clinical trials that help Utah families battling cancer. It funds suicide prevention programs in our schools, mental health outreach in rural counties, and pediatric care innovations at Primary Children's Hospital (PCH). It supports research for Native American communities and families dealing with chronic conditions like diabetes and asthma. Without that funding, many of these programs would disappear. I've seen the impact of public health investment firsthand. After I tested positive for latent tuberculosis as a student, I received free weekly treatment and health monitoring through the Utah County Health Department. It was science-backed care, delivered through a local system supported by federal resources. Without that treatment, I could have developed active tuberculosis — a threat not just to me but also to others. The system worked because it was built on scientific research and proactive policy. That kind of safety net doesn't happen without sustained funding. Furthermore, my nephew, Wesley, was cared for at PCH when he was just four months old. He was diagnosed with polyarteritis nodosa, a rare autoimmune disease that causes inflammation and damage to the heart. The NIH not only funds various programs at PCH but also was crucial to backing the science that led to properly diagnosing and saving Wesley. These cuts hurt the next generation. Graduate students and early career scientists — many of whom come from Utah — rely on federal research grants to get their start. If funding dries up, so do those opportunities. We risk losing promising young minds to other careers or other countries. This is not a partisan issue. Scientific progress should never be about politics. Every Utahn benefits from the medications they take, the clean water they drink, the safe food they eat and the medical care they receive. All of these are underpinned by science. Restricting it weakens our shared safety net and quality of life. Utah is built on hard work, innovation and foresight. Cutting science funding now would undermine the very foundation that allows us to adapt, compete and care for our communities. Science works for Utah — let's keep it that way.
Yahoo
2 hours ago
- Yahoo
Navarro ‘not glad or whatever' about Musk exit
White House trade adviser Peter Navarro told reporters early Friday he is 'not glad or whatever' about Elon Musk's exit, comments that came one day after Musk and President Trump publicly feuded online. 'I'm not glad or whatever … People come and go from the White House,' Navarro said when asked whether he was glad to see Musk 'out of the fray,' given their disagreements over tariffs. Navarro noted Musk's status as a special government employee, which was limited to 130 days. Navarro added that he and members of the advisory Department of Government Efficiency were working on 'a very special project' regarding one unidentified agency. 'We've taken a computer program that's very important, that is run like a 1950s IBM punch card operation at great expense to the American people,' he said, 'and we're going to turn that from a Model T into a Ferrari, and it's going to transform a bunch of people's lives and save American taxpayers a lot of money.' Navarro and Musk have not always seen eye to eye, particularly over the issue of tariffs and Tesla, which the tech mogul co-founded and leads. Musk notably trashed Navarro on X in April, calling him 'truly a moron' after Navarro described Tesla as a 'car assembler' instead of 'car manufacturer.' The two have been at odds over tariffs, with Musk being a vocal opponent of the strategy. Navarro told reporters on Friday that while 'we can have disagreements' over tariffs, 'I would simply say that everybody during our first term who said that the tariffs were going to be recessionary and inflationary were obviously, obviously and widely wrong. All we got was price stability and growth.' A spectacular online feud erupted between Musk and Trump on Thursday, which quickly became personal between the former allies. Earlier this week, Musk slammed Trump's megabill in Congress, calling it a post on X 'massive, outrageous, pork-filled Congressional spending bill' and a 'disgusting abomination.' Trump expressed his disappointment over Musk's remarks during an Oval Office meeting on Thursday. He knew every aspect of this bill. He knew it better than almost anybody. And he never had a problem until right after he left,' the president said. 'I'm very disappointed in Elon. I've helped Elon a lot.' The situation quickly devolved after Trump mused that Musk maybe missed being in the White House, with Musk taking credit for Trump's win during the November election and claiming the president has ties to convicted sex offender and financier Jeffrey Epstein, who died in prison while awaiting trial. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
TechCrunch
3 hours ago
- TechCrunch
Startups Weekly: It's buying season
Welcome to Startups Weekly — your weekly recap of everything you can't miss from the world of startups. Want it in your inbox every Friday? Sign up here. From acquiring stealth startups to larger ones, and from funding Series A to Series G rounds, buyers and investors made for a busy news cycle. Most interesting startup stories from the week Image Credits:Paco Freire/SOPA Images/LightRocket via Getty Images This week must have seemed like the perfect time for companies to announce their latest startup acquisitions. Unlocked: Israeli phone unlocking firm Cellebrite acquired mobile testing startup Corellium for $170 million in cash, with $20 million converted to equity at closing. Sought and found: IBM acquired Seek AI, an AI platform that lets users ask questions about enterprise data using natural language. Its technology is set to become a key part of Watsonx AI Labs, IBM's new NYC-based AI accelerator. Data access: Data governance platform Collibra acquired Raito, a startup that had raised $4 million to date to help companies manage which employees and customers have access to internal data. Both Collibra and Raito are based in Brussels. Challenger: AMD acquired Brium, a stealth startup focusing on AI software optimization, in a deal that appears intended to challenge Nvidia's AI hardware dominance. Techcrunch event Save $200+ on your TechCrunch All Stage pass Build smarter. Scale faster. Connect deeper. Join visionaries from Precursor Ventures, NEA, Index Ventures, Underscore VC, and beyond for a day packed with strategies, workshops, and meaningful connections. Save $200+ on your TechCrunch All Stage pass Build smarter. Scale faster. Connect deeper. Join visionaries from Precursor Ventures, NEA, Index Ventures, Underscore VC, and beyond for a day packed with strategies, workshops, and meaningful connections. Boston, MA | REGISTER NOW Crunchy: Snowflake disclosed it plans to buy Crunchy Data, a startup that helps companies build with Postgres. The cloud data platform company declined to comment on the deal's valuation, but a source estimated it at around $250 million. No more pesto: Data-labeling startup Scale AI hired the team behind Pesto AI, which is shutting down after raising more than $8 million to help companies recruit developers remotely. Hmm: Airtime, the video startup from Evernote's founder Phil Libin, laid off dozens of employees, who won't be invited to stay for the next 'season.' The company, formerly known as mmhmm, raised nearly $135 million in venture funding across multiple early-stage rounds. Ouch: Indian grocery startup KiranaPro confirmed that it was hacked last May. All of its data was wiped in the attack. The legal battle continues: HR tech startup Deel accused rival Rippling of hiring an employee who spent six months impersonating a customer, but Rippling also issued an amended complaint regarding its corporate spying accusations against Deel. Most interesting VC and funding news this week Image Credits:Kyle Grillot/Bloomberg / Getty Images Money once again flew uphill this week, but some funding also went to startups that hope to challenge market leaders, expand internationally, and make roads safer. Lucky Luckey: Defense tech startup Anduril raised a gigantic $2.5 billion Series G round, including a $1 billion investment from Founders Fund, doubling the company's valuation to $30.5 billion in the process. Moving the cursor: Anysphere, the maker of AI coding assistant Cursor, has raised $900 million at a $9.9 billion valuation. Sources said the company has surpassed $500 million in annual recurring revenue. Brain chips: Neuralink, Elon Musk's brain computer interface startup, secured a $650 million Series E, reportedly at a pre-money valuation around $9 billion. Insured: Bolttech, a Singapore-based insurtech company specializing in embedded insurance, completed a $147 million Series C at a $2.1 billion valuation. APUs vs. GPUs: Speedata, an Israeli chip startup competing with Nvidia, raised a $44 million Series B. The company is developing an analytics processing unit (APU) to accelerate AI and data workloads, which it will showcase later this month. From Ireland to Japan: Irish fintech startup Nomupay locked in a $40 million Series C from SB Payment Service (SBPS), a subsidiary of Japanese telco giant SoftBank Corp. It will use the capital on expanding its reach in key regions, including Asia, as well as on acquisitions. Drive with care: Obvio, a startup using AI and cameras installed on stop signs to detect unsafe driving, raised a $22 million Series A led by Bain Capital Ventures. Richest slice: Between February and May of this year, North American AI startups attracted $69.7 billion in venture capital across 1,528 deals, far exceeding Europe's $6.4 billion (742 deals) and Asia's $3 billion (515 deals), according to PitchBook data. Last but not least Image Credits:Slava Blazer for TechCrunch / Elad Gil began investing in AI startups like Perplexity and Harvey well before most VCs recognized the trend. Now he's placing bets on traditional businesses that AI can help reinvent and make more lucrative.
